JP2009531463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531463A5 JP2009531463A5 JP2009503253A JP2009503253A JP2009531463A5 JP 2009531463 A5 JP2009531463 A5 JP 2009531463A5 JP 2009503253 A JP2009503253 A JP 2009503253A JP 2009503253 A JP2009503253 A JP 2009503253A JP 2009531463 A5 JP2009531463 A5 JP 2009531463A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- cell group
- percentage
- lymphoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 10
- 102100022297 Integrin alpha-X Human genes 0.000 claims 10
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 5
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 5
- 102100022338 Integrin alpha-M Human genes 0.000 claims 5
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 210000000952 spleen Anatomy 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- 108700012434 CCL3 Proteins 0.000 claims 1
- 229940078811 CD11b antagonist Drugs 0.000 claims 1
- 229940104228 CD18 antagonist Drugs 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 229940123313 MCP-1 antagonist Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000002435 cytoreductive effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78772006P | 2006-03-29 | 2006-03-29 | |
| PCT/US2007/065377 WO2007115045A2 (en) | 2006-03-29 | 2007-03-28 | Diagnostics and treatments for tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531463A JP2009531463A (ja) | 2009-09-03 |
| JP2009531463A5 true JP2009531463A5 (enExample) | 2010-05-20 |
Family
ID=38564192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503253A Pending JP2009531463A (ja) | 2006-03-29 | 2007-03-28 | 腫瘍の診断と治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20070264193A1 (enExample) |
| EP (1) | EP1999151A2 (enExample) |
| JP (1) | JP2009531463A (enExample) |
| KR (1) | KR20080106946A (enExample) |
| CN (1) | CN101448856A (enExample) |
| AR (1) | AR060228A1 (enExample) |
| AU (1) | AU2007233237A1 (enExample) |
| BR (1) | BRPI0709425A2 (enExample) |
| CA (1) | CA2647430A1 (enExample) |
| CL (1) | CL2007000876A1 (enExample) |
| CR (1) | CR10325A (enExample) |
| IL (1) | IL193842A0 (enExample) |
| MA (1) | MA30348B1 (enExample) |
| MX (1) | MX2008012279A (enExample) |
| NO (1) | NO20084546L (enExample) |
| RU (1) | RU2008142775A (enExample) |
| TW (1) | TW200806322A (enExample) |
| WO (1) | WO2007115045A2 (enExample) |
| ZA (1) | ZA200807590B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US20100196509A1 (en) | 2005-02-28 | 2010-08-05 | Jonathan Braun | Methods for Diagnosis and Treatment of Endometrial Cancer |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| JP2010518839A (ja) * | 2007-02-21 | 2010-06-03 | アブリンクス エン．ヴェー． | 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド |
| EP2227556B1 (en) * | 2007-11-19 | 2014-08-27 | Celera Corporation | Lung cancer markers and uses thereof |
| WO2009075768A2 (en) * | 2007-12-07 | 2009-06-18 | Children's Hospital Of Orange County | Optical device and method for real-time chemosensitivity testing |
| EP2649995A3 (en) * | 2008-02-29 | 2014-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of post-radiation tumor growth |
| WO2010017083A1 (en) * | 2008-08-04 | 2010-02-11 | Wayne State University | Methods of treating cancer with cd11b antibodies |
| JP2012501188A (ja) * | 2008-08-29 | 2012-01-19 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆ非依存性腫瘍についての診断薬および治療 |
| WO2010046889A1 (en) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for delivery of sirna to bone marrow cells and uses thereof |
| EP2379059A4 (en) * | 2008-12-10 | 2012-10-31 | Anhui Zhongren Technology Co Ltd | COMPOSITION WITH CONTROLLED RELEASE |
| KR101596539B1 (ko) * | 2008-12-23 | 2016-02-22 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| US7615353B1 (en) | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| JP2013500993A (ja) * | 2009-07-31 | 2013-01-10 | ジェネンテック， インコーポレイテッド | Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害 |
| KR20120059553A (ko) * | 2009-08-14 | 2012-06-08 | 제넨테크, 인크. | Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커 |
| US7736861B1 (en) | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| JP5911805B2 (ja) | 2009-11-20 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ） |
| WO2011103599A2 (en) * | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
| US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| KR101313184B1 (ko) * | 2010-06-24 | 2013-09-30 | 한국표준과학연구원 | 질병 지표 검출 키트 및 질병 지표 검출 방법 |
| MX2014001736A (es) * | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| RU2502471C9 (ru) * | 2012-08-21 | 2015-04-20 | Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") | Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики |
| EP2741086A1 (en) * | 2012-12-06 | 2014-06-11 | Ludwig Boltzmann Gesellschaft | Method for measuring coagulation of blood samples using viscoelastic tests (VET) |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| RU2546105C1 (ru) * | 2014-04-29 | 2015-04-10 | Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") | Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет |
| EP3532498A1 (en) * | 2016-10-31 | 2019-09-04 | Hexal AG | Antibody preparation |
| WO2020023183A1 (en) * | 2018-07-24 | 2020-01-30 | So Young Life Sciences Corporation | Use of liposomes to deliver a protein and a gene encoding the protein to a live cell |
| US20200347449A1 (en) * | 2019-05-01 | 2020-11-05 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| CN112946291A (zh) * | 2019-12-10 | 2021-06-11 | 上海交通大学医学院附属仁济医院 | Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840793A (en) * | 1987-06-11 | 1989-06-20 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE4422551C1 (de) * | 1994-06-28 | 1995-07-27 | Daimler Benz Ag | Durch Servomotor unterstützte Zahnstangenlenkung |
| US5871697A (en) * | 1995-10-24 | 1999-02-16 | Curagen Corporation | Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
| ES2236634T3 (es) * | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU4972900A (en) * | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| PL359653A1 (en) * | 2000-06-23 | 2004-08-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| AU2003215163A1 (en) * | 2002-02-12 | 2003-09-04 | Vanderbilt University | Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20060009360A1 (en) * | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
-
2007
- 2007-03-28 KR KR1020087023600A patent/KR20080106946A/ko not_active Withdrawn
- 2007-03-28 MX MX2008012279A patent/MX2008012279A/es active IP Right Grant
- 2007-03-28 EP EP07759590A patent/EP1999151A2/en not_active Withdrawn
- 2007-03-28 AU AU2007233237A patent/AU2007233237A1/en not_active Abandoned
- 2007-03-28 ZA ZA200807590A patent/ZA200807590B/xx unknown
- 2007-03-28 CA CA002647430A patent/CA2647430A1/en not_active Abandoned
- 2007-03-28 US US11/692,681 patent/US20070264193A1/en not_active Abandoned
- 2007-03-28 JP JP2009503253A patent/JP2009531463A/ja active Pending
- 2007-03-28 RU RU2008142775/14A patent/RU2008142775A/ru not_active Application Discontinuation
- 2007-03-28 BR BRPI0709425-6A patent/BRPI0709425A2/pt not_active IP Right Cessation
- 2007-03-28 WO PCT/US2007/065377 patent/WO2007115045A2/en not_active Ceased
- 2007-03-28 CN CNA2007800184412A patent/CN101448856A/zh active Pending
- 2007-03-29 TW TW096111126A patent/TW200806322A/zh unknown
- 2007-03-29 CL CL200700876A patent/CL2007000876A1/es unknown
- 2007-03-29 AR ARP070101340A patent/AR060228A1/es not_active Application Discontinuation
-
2008
- 2008-09-02 IL IL193842A patent/IL193842A0/en unknown
- 2008-09-29 CR CR10325A patent/CR10325A/es not_active Application Discontinuation
- 2008-10-20 MA MA31315A patent/MA30348B1/fr unknown
- 2008-10-28 NO NO20084546A patent/NO20084546L/no not_active Application Discontinuation
-
2010
- 2010-04-28 US US12/769,004 patent/US20100239568A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531463A5 (enExample) | ||
| RU2008142775A (ru) | Диагностика и лечение опухолей | |
| Müller Bark et al. | Circulating biomarkers in patients with glioblastoma | |
| US10328072B2 (en) | Treatment of lung cancer using hedgehog pathway inhibitors | |
| Antlanger et al. | Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis | |
| CA2711843A1 (en) | Her-2 diagnostic methods | |
| Migliorini et al. | Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus | |
| WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
| WO2010099137A3 (en) | In situ methods for monitoring the emt status of tumor cells in vivo | |
| JP2010526104A5 (enExample) | ||
| Song et al. | Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging | |
| Kawamura et al. | Synthesis and evaluation of [11C] XR9576 to assess the function of drug efflux transporters using PET | |
| CA2798181A1 (en) | Combination therapy and method for assessing resistance to treatment | |
| El-Subbagh et al. | Cytarabine | |
| US10261085B2 (en) | Treating bladder cancer patients and identifying bladder cancer patients responsive to treatment | |
| Mengqi et al. | Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2019 | |
| JP2009507234A5 (enExample) | ||
| Zhou et al. | Molecular Imaging of Renin Activity using Fluorogenic Nanoprobes for Precision Antihypertensive Therapy | |
| Luo et al. | Macrophage Vesicles‐Loaded NIR‐II AIEgens for Precise In Situ Fluorescence Imaging of Atherosclerosis | |
| JP2012127879A (ja) | 腎症の進行度の判定方法並びに線維化抑制剤。 | |
| Kiyono et al. | Evaluation of radioiodinated (2S, αS)-2-(α-(2-iodophenoxy) benzyl) morpholine as a radioligand for imaging of norepinephrine transporter in the heart | |
| CN204855535U (zh) | 一种用于诊断中性粒细胞明胶酶相关脂质运载蛋白的试剂盒 | |
| 승혁최 et al. | Clinical Utility of Donor-Derived Cell-Free DNA Testing in Kidney Transplant Recipients | |
| JP2025524379A (ja) | 膵臓がんにおけるバイオマーカー | |
| Fang et al. | In silico design and preclinical evaluation of a novel Trop2-targeted peptide tracer for PET imaging of tumors |